Literature DB >> 28698951

How to report adherence to treatment as clinically relevant data-making a case of CML and TKI.

Lucas Miyake Okumura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28698951     DOI： 10.1007/s00520-017-3809-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  10 in total

1.  Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Authors:  Massimo Breccia; Fabio Efficace; Giuliana Alimena
Journal:  Leuk Res       Date:  2012-03-27       Impact factor: 3.156

2.  Modelling the association between adherence and viral load in HIV-infected patients.

Authors:  Bernard Vrijens; Els Goetghebeur; Erik de Klerk; Richard Rode; Steve Mayer; John Urquhart
Journal:  Stat Med       Date:  2005-09-15       Impact factor: 2.373

3.  Compliance, concordance, adherence.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-04       Impact factor: 4.335

Review 4.  Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.

Authors:  Joëlle Guilhot; Claude Preudhomme; Francois Xavier Mahon; François Guilhot
Journal:  Cancer       Date:  2014-10-24       Impact factor: 6.860

Review 5.  Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.

Authors:  Adam Gater; Louise Heron; Linda Abetz-Webb; John Coombs; Jeff Simmons; François Guilhot; Delphine Rea
Journal:  Leuk Res       Date:  2012-02-23       Impact factor: 3.156

6.  Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.

Authors:  Prasanth Ganesan; Tenali Gnana Sagar; Biswajit Dubashi; Rejiv Rajendranath; Krishnarathinam Kannan; Sanju Cyriac; Manjunath Nandennavar
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

7.  The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms.

Authors:  Silmara Mendes Martins Moulin; Frederico Jacob Eutrópio; Jessica de Oliveira Souza; Fernanda de Oliveira Busato; David N Olivieri; Carlos Eduardo Tadokoro
Journal:  Support Care Cancer       Date:  2016-11-19       Impact factor: 3.603

Review 8.  A new taxonomy for describing and defining adherence to medications.

Authors:  Bernard Vrijens; Sabina De Geest; Dyfrig A Hughes; Kardas Przemyslaw; Jenny Demonceau; Todd Ruppar; Fabienne Dobbels; Emily Fargher; Valerie Morrison; Pawel Lewek; Michal Matyjaszczyk; Comfort Mshelia; Wendy Clyne; Jeffrey K Aronson; J Urquhart
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

9.  Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment.

Authors:  Lucas M Okumura; Valquíria D Antunes; Karina S Aguiar; Tatiane Farias; Vânia M Andrzejevski; Vaneuza M Funke
Journal:  Pharm Pract (Granada)       Date:  2015-06-15

10.  Predictive validity of a medication adherence measure in an outpatient setting.

Authors:  Donald E Morisky; Alfonso Ang; Marie Krousel-Wood; Harry J Ward
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-05       Impact factor: 2.885
  10 in total
  3 in total

1.  Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents.

Authors:  Charles W Given; Barbara A Given; Alla Sikorskii; John C Krauss; Eric Vachon
Journal:  Support Care Cancer       Date:  2018-08-23       Impact factor: 3.603

2.  Adherence to TKI in CML patients: more than reports.

Authors:  Jessica de O Souza; Fernanda de O Busato; Isadora Duarte Santos Frota; Daniel Santos Neves; Marcelo Renan de Deus Santos; David N Olivieri; Carlos E Tadokoro
Journal:  Support Care Cancer       Date:  2017-11-18       Impact factor: 3.603

3.  Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees.

Authors:  Krish Patel; Vinjamuri S Sudhir; Shaum Kabadi; Joanna C Huang; Sanchita Porwal; Kushan Thakkar; John M Pagel
Journal:  J Oncol Pharm Pract       Date:  2019-02-05       Impact factor: 1.809
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.